Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
about
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancerBeyond taxanes: the next generation of microtubule-targeting agentsComplexities of TGF-β targeted cancer therapy.Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesA comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Critical appraisal of cabazitaxel in the management of advanced prostate cancerPooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.Fool's gold, lost treasures, and the randomized clinical trial.First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.Eribulin -- a review of preclinical and clinical studies.Global experience with ixabepilone in breast cancer.Ixabepilone for the treatment of breast cancer.Recent developments in treatment stratification for metastatic breast cancer.Pharmacokinetic evaluation of capecitabine in breast cancer.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.A phase I study of oral ixabepilone in patients with advanced solid tumors.Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
P2860
Q24633167-471C223F-A1D5-45A3-AA43-A4FCE90F28C6Q26865369-BCC64D6A-45D7-458E-A04A-E1D26531ED7BQ27693607-488E55D0-0C75-46D3-A6EF-2B558E82CDDEQ28080469-C55A5632-9B3D-436A-8D5A-73CE43D0D5D9Q33430813-B62B6824-C146-4680-AF19-975E58DBF489Q34386577-5ACF51BA-285A-46BE-8FE4-DC7E42E318F6Q34458907-39332A93-5E36-433D-B937-EB16DFDC591FQ34669260-0E16EFAD-875D-422F-8F1F-EE5BD31CA5F2Q34993796-D9427E08-96E5-4728-8EB0-6C8F4B72550DQ35721526-49F82076-5B36-4CF2-A932-BD23A4920D06Q35872691-617611AC-927E-4233-8C99-BAEFBC9B0187Q36132957-C66EDC1D-BF8C-4924-9C00-2C115E199633Q36714374-031736F1-BEB5-4B09-9D47-56A4F17DAFA2Q37236305-3C68F7AA-50DF-4475-8465-063537065945Q37292020-2BDF0964-5D64-4E43-9681-85E53361D623Q37637936-72AB66D2-E922-45B5-B7E3-A25153043564Q37873462-5276B058-43DE-4F36-A60E-CE54EA5C28F3Q37876407-1DC1DDB4-7BC1-49B9-8C18-428DCA1D48D8Q37950515-746530E7-BE75-456F-884D-D97AF12DCF0BQ38072718-537E6285-6F25-4BCB-A313-2056FCB24E91Q38099046-669FE93C-A06D-4A10-B2E1-50DC9BBC21C6Q38245797-358BF04C-3685-4495-8D93-71A586A30DC1Q38527538-2077EE4F-14C7-41FD-9DCE-2974414DA21AQ38682028-EB1F21B2-7535-4831-8307-97FC5942F752Q40213089-B434848A-2EEC-4DAF-8C93-60E923F701B9Q50943615-CB6CA7AB-5485-4912-944D-CEBAFA66D47EQ54685246-E63681DB-4E33-4D30-B2F6-8A6EDF10691BQ54963093-0F72475C-B855-41D5-A1B9-F722F325B018
P2860
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Analysis of overall survival f ...... to anthracyclines and taxanes.
@en
Analysis of overall survival f ...... to anthracyclines and taxanes.
@nl
type
label
Analysis of overall survival f ...... to anthracyclines and taxanes.
@en
Analysis of overall survival f ...... to anthracyclines and taxanes.
@nl
prefLabel
Analysis of overall survival f ...... to anthracyclines and taxanes.
@en
Analysis of overall survival f ...... to anthracyclines and taxanes.
@nl
P2093
P2860
P1476
Analysis of overall survival f ...... to anthracyclines and taxanes.
@en
P2093
Fernando Hurtado de Mendoza
Gabriel N Hortobagyi
Guillermo L Lerzo
Henri H Roché
Henry L Gomez
Hyun-Cheol Chung
Luis E Fein
Pralay Mukhopadhyay
Ronald A Peck
P2860
P2888
P304
P356
10.1007/S10549-010-0901-4
P407
P577
2010-05-08T00:00:00Z
P5875
P6179
1029800309